Background: ALPHA-STAR (NCT05695248) is an ongoing phase 1b/2 clinical trial in patients with HAE, investigating safety and efficacy of STAR-0215, humanized monoclonal antibody inhibitor of plasma kallikrein with long-lasting activity enabled by a YTE-modified Fc domain. This evidence concerns the gene KLK4 and hereditary angioedema.